NEW YORK (GenomeWeb News) – Advion said on Monday it has signed an exclusive original equipment manufacturing and distribution partnership deal with Swiss firm CAMAG for Advion's TLC/MS interface product.

The two companies plan to commercialize a combined system to Advion's Synthetic Organic Chemistry and Peptide Synthesis global market segments, Advion said, adding it has exclusive marketing and support rights in certain geographies, including North America and parts of Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.